Vaxart Inc

Vaxart Inc(VXRT)股票分析

$0.320

-0.080 (-25.06%)收盘时

Loading chart…
High
0.430
Open
0.412
VWAP
0.35
Vol
24.02M
Mkt Cap
118.17M
Low
0.300
Amount
8.41M
EV/EBITDA, TTM
-7.36

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.

vaxart.com

估值指标

The current forward P/E ratio for Vaxart Inc (VXRT) is -1.49, compared to its 5-year average forward P/E of -3.00.

Forward P/E

Fair
5Y Average P/E
-3.00
Current P/E
-1.49
高估
-0.25
低估
-5.74

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-3.80
Current EV/EBITDA
-7.36
高估
5.19
低估
-12.79

Forward P/S

Fair
5Y Average P/S
222.12
Current P/S
3.41
高估
695.35
低估
-251.11

Alphio AI Price Scenarios for VXRT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%VXRT

$1.66

情景价格

B

Base

Base · 50%VXRT

$1.28

情景价格

B

Bear

Bear · 25%VXRT

$0.91

情景价格

事件时间线

2026-07-06 (ET)

16:30:00

Vaxart Announces Safety Data from COVID-19 Oral Vaccine Trial

2026-07-01 (ET)

16:30:00

Vaxart Resolves Proxy Contest, Seeks Independent Director

2026-06-25 (ET)

09:30:00

Vaxart Secures $29M Funding for Oral Vaccine Trial

2026-01-15 (ET)

08:20:00

Vaxart Publishes Phase 1 Trial Data Showing Vaccine Efficacy in Breastfeeding Women

2025-11-05 (ET)

16:03:09

Dynavax Secures Licensing Deal for Vaxart's Oral COVID-19 Vaccine Initiative

资讯

VXRT FAQ — answered by Alphio AI

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始